First-pass extracted concept

HER2-positive oesophagogastric adenocarcinoma

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

HER2 is overexpressed in ~20% of patients with oesophagogastric adenocarcinoma (EGA).

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1pathway associationsupports2025Source 1DOI PubMed

In HER2-positive oesophagogastric adenocarcinoma, aberrant PI3K/AKT and MAPK/ERK signalling enhance tumour cell survival and proliferation.

Quoted textsource-backed

In HER2-positive EGA, aberrant signalling pathways, such as PI3K/AKT and MAPK/ERK, enhance tumour cell survival and proliferation...

Claim 2pathway associationsupports2025Source 1DOI PubMed

In HER2-positive oesophagogastric adenocarcinoma, upregulation of VEGF fosters vascularization that supports tumour metabolic demands and proliferation.

Quoted textsource-backed

upregulation of angiogenic factors like VEGF fosters vascularization, meeting a tumour's metabolic demands and facilitating its proliferation.

Claim 3prevalencesupports2025Source 1DOI PubMed

HER2 is overexpressed in approximately 20% of patients with oesophagogastric adenocarcinoma.

Quoted textsource-backed

HER2 (human epidermal growth factor receptor 2) is a receptor tyrosine kinase which is overexpressed in ~20% of patients with oesophagogastric adenocarcinoma (EGA).